Evidence map›Paper›PMID 36156752›Full record

Observational studyDigestive diseases and sciences2023

Antibody Response and Safety of ChAdOx1-nCOV (Covishield) in Patients with Cirrhosis: A Cross-Sectional, Observational Study.

Amandeep Singh, Arka De, Mini P Singh, Sahaj Rathi, Nipun Verma, Madhumita Premkumar, Sunil Taneja, Ajay Duseja, Virendra Singh

Open access · bronzeAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Vaccination Strategies for a Liver Transplant Recipient.Journal of clinical and experimental hepatology
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Amandeep SinghDepartment of Hepatology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Arka DeDepartment of Hepatology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Mini P SinghDepartment of Virology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Sahaj RathiDepartment of Hepatology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Nipun VermaDepartment of Hepatology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Madhumita PremkumarDepartment of Hepatology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Sunil TanejaDepartment of Hepatology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Ajay DusejaDepartment of Hepatology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India.
Virendra SinghDepartment of Hepatology, Post-Graduate Institute of Medical Education and Research, Chandigarh, India. virendrasingh100@hotmail.com.ORCID 0000-0002-9113-5167
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with cirrhosis have a higher risk of severe COVID-19 and mortality and are high-priority patients for vaccination. However, cirrhotics were excluded from the phase 2/3 vaccine trials. Hence, we aimed to assess the antibody response and safety of Covishield (ChAdOx1nCoV-19) among patients with cirrhosis.

methodsPatients who attended the tele-hepatology services at our institute from March 2020 to June 2021 and diagnosed with cirrhosis as per their medical records were telephonically interviewed in July 2021 using a pre-specified questionnaire. Patients who had completed 2 doses of ChAdOx1-nCOV (with the 2

resultsWe interviewed 784 patients with cirrhosis. At least 1 dose of ChAdOx1-nCOV was received by 231 patients among whom 134 (58%) had received 2 doses. Documented COVID-19 was reported in 3.9% patients who received at least 1 dose of ChAdOx1-nCOV including breakthrough infections in 3.7% patients vaccinated with 2 doses. Local and systemic adverse events were reported by 42% and 22.1% patients. None developed anaphylaxis, acute decompensation, acute-on-chronic liver failure, or other serious adverse events requiring hospitalization. Seroconversion was documented in 81 (92%) out of 88 patients. No difference was observed in level of antibody response between patients with compensated and decompensated cirrhosis (p = 0.12).

conclusionOur preliminary data suggest that ChAdOx1-nCOV is safe with high seroconversion rates in patients with cirrhosis.

Indexed as

ChAdOx1 nCoV-19COVID-19Antibody FormationCross-Sectional StudiesHumansLiver CirrhosisSARS-CoV-2VaccinationChAdOx1 nCoV-19PandemicSARS-COV2Serum Institute of IndiaVaccines

Identifiers

PMID36156752
PMCPMC9510448
OpenAlexW4297047330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.